Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.
| MER Indicator |
MER description |
Target Fiscal Year |
Target |
| CARE_CURR |
Age/sex: <1 Female |
2016 |
34 |
| CARE_CURR |
Age/sex: <1 Female |
2016 |
139 |
| CARE_CURR |
Age/sex: <1 Male |
2016 |
139 |
| CARE_CURR |
Age/sex: <1 Male |
2016 |
33 |
| CARE_CURR |
Age/sex: 1-4 Female |
2016 |
195 |
| CARE_CURR |
Age/sex: 1-4 Female |
2016 |
262 |
| CARE_CURR |
Age/sex: 1-4 Male |
2016 |
260 |
| CARE_CURR |
Age/sex: 1-4 Male |
2016 |
193 |
| CARE_CURR |
Age/sex: 10-14 Female |
2016 |
373 |
| CARE_CURR |
Age/sex: 10-14 Female |
2016 |
602 |
| CARE_CURR |
Age/sex: 10-14 Male |
2016 |
314 |
| CARE_CURR |
Age/sex: 10-14 Male |
2016 |
600 |
| CARE_CURR |
Age/sex: 15-19 Female |
2016 |
1,138 |
| CARE_CURR |
Age/sex: 15-19 Female |
2016 |
1,567 |
| CARE_CURR |
Age/sex: 15-19 Male |
2016 |
646 |
| CARE_CURR |
Age/sex: 15-19 Male |
2016 |
943 |
| CARE_CURR |
Age/sex: 20-24 Female |
2016 |
1,709 |
| CARE_CURR |
Age/sex: 20-24 Female |
2016 |
3,934 |
| CARE_CURR |
Age/sex: 20-24 Male |
2016 |
1,008 |
| CARE_CURR |
Age/sex: 20-24 Male |
2016 |
2,201 |
| CARE_CURR |
Age/sex: 25-49 Female |
2016 |
6,241 |
| CARE_CURR |
Age/sex: 25-49 Female |
2016 |
52,099 |
| CARE_CURR |
Age/sex: 25-49 Male |
2016 |
4,019 |
| CARE_CURR |
Age/sex: 25-49 Male |
2016 |
9,422 |
| CARE_CURR |
Age/sex: 5-9 Female |
2016 |
238 |
| CARE_CURR |
Age/sex: 5-9 Female |
2016 |
392 |
| CARE_CURR |
Age/sex: 5-9 Male |
2016 |
390 |
| CARE_CURR |
Age/sex: 5-9 Male |
2016 |
209 |
| CARE_CURR |
Age/sex: 50+ Female |
2016 |
2,026 |
| CARE_CURR |
Age/sex: 50+ Female |
2016 |
1,384 |
| CARE_CURR |
Age/sex: 50+ Male |
2016 |
1,603 |
| CARE_CURR |
Age/sex: 50+ Male |
2016 |
1,405 |
| CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female |
2016 |
28 |
| CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male |
2016 |
23 |
| CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female |
2016 |
448 |
| CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male |
2016 |
264 |
| CARE_CURR |
Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load |
2016 |
75,738 |
| CARE_CURR |
Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load |
2016 |
19,979 |
| CARE_CURR |
Sum of Age/Sex disaggregates |
2016 |
19,979 |
| CARE_CURR |
Sum of Age/Sex disaggregates |
2016 |
75,739 |
| CARE_CURR |
Sum of Aggregated Age/Sex disaggregates |
2016 |
763 |
| CARE_NEW |
Age/sex: <1 Female |
2016 |
14 |
| CARE_NEW |
Age/sex: <1 Male |
2016 |
14 |
| CARE_NEW |
Age/sex: 1-4 Female |
2016 |
24 |
| CARE_NEW |
Age/sex: 1-4 Male |
2016 |
26 |
| CARE_NEW |
Age/sex: 10-14 Female |
2016 |
71 |
| CARE_NEW |
Age/sex: 10-14 Male |
2016 |
66 |
| CARE_NEW |
Age/sex: 15-19 Female |
2016 |
228 |
| CARE_NEW |
Age/sex: 15-19 Male |
2016 |
146 |
| CARE_NEW |
Age/sex: 20-24 Female |
2016 |
465 |
| CARE_NEW |
Age/sex: 20-24 Male |
2016 |
279 |
| CARE_NEW |
Age/sex: 25-49 Female |
2016 |
3,127 |
| CARE_NEW |
Age/sex: 25-49 Male |
2016 |
999 |
| CARE_NEW |
Age/sex: 5-9 Female |
2016 |
34 |
| CARE_NEW |
Age/sex: 5-9 Male |
2016 |
31 |
| CARE_NEW |
Age/sex: 50+ Female |
2016 |
443 |
| CARE_NEW |
Age/sex: 50+ Male |
2016 |
264 |
| CARE_NEW |
Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load |
2016 |
6,231 |
| CARE_NEW |
Sum of Age/sex disaggregates |
2016 |
6,231 |
| FN_THER |
Age: <1 |
2016 |
11 |
| FN_THER |
Age: 1-4 |
2016 |
23 |
| FN_THER |
Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period |
2016 |
166 |
| FN_THER |
Number of PLHIV who were nutritionally assessed and found to be clinically undernourished |
2016 |
166 |
| FN_THER |
Sum of Age disaggregates |
2016 |
166 |
| FPINT_SITE |
Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services |
2016 |
15 |
| FPINT_SITE |
Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment |
2016 |
15 |
| HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female |
2016 |
4,350 |
| HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male |
2016 |
4,412 |
| HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female |
2016 |
33,674 |
| HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male |
2016 |
22,089 |
| HTS_TST |
By Test Result: Negative |
2016 |
97,163 |
| HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2016 |
105,568 |
| HTS_TST |
Sum of Aggregated Age/Sex <15 |
2016 |
8,762 |
| HTS_TST |
Sum of Aggregated Age/Sex 15+ |
2016 |
55,763 |
| HTS_TST |
Sum of Aggregated Age/Sex disaggregates |
2016 |
64,525 |
| HTS_TST |
Sum of Test Result disaggregates |
2016 |
105,568 |
| HTS_TST_POS |
By Test Result: Positive |
2016 |
8,405 |
| LAB_ACC |
Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation |
2016 |
1 |
| LAB_CAP |
By clinical laboratories |
2016 |
12 |
| LAB_CAP |
Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests |
2016 |
30 |
| LAB_PT |
CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program |
2016 |
12 |
| LAB_PT |
CD4: Number of laboratories that participate in this PT program |
2016 |
12 |
| LAB_PT |
CD4: Number of laboratories that perform this testing |
2016 |
12 |
| LAB_PT |
HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program |
2016 |
11 |
| LAB_PT |
HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program |
2016 |
11 |
| LAB_PT |
HIV serologic/diagnostic testing: Number of laboratories that perform this testing |
2016 |
11 |
| PMTCT_ARV |
Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) |
2016 |
487 |
| PMTCT_ARV |
Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery |
2016 |
487 |
| PMTCT_ARV |
Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy |
2016 |
147 |
| PMTCT_ARV |
Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy |
2016 |
340 |
| PMTCT_ARV |
Sum of New and Current disaggregates |
2016 |
487 |
| PMTCT_EID |
By infants who received a virologic test within 2 months of birth |
2016 |
449 |
| PMTCT_EID |
Number of infants who had a virologic HIV test within 12 months of birth during the reporting period |
2016 |
449 |
| PMTCT_EID |
Sum of Infant Age disaggregates |
2016 |
449 |
| PMTCT_STAT |
By: Known positives at entry |
2016 |
1,050 |
| PMTCT_STAT |
By: Number of new positives identified |
2016 |
1,406 |
| PMTCT_STAT |
Number of new ANC and L&D clients |
2016 |
31,078 |
| PMTCT_STAT |
Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) |
2016 |
28,331 |
| PMTCT_STAT |
Sum of Positives Status disaggregates |
2016 |
2,456 |
| TB_SCREEN |
Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load |
2016 |
75,738 |
| TB_SCREEN |
Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load |
2016 |
19,979 |
| TX_CURR |
Age/Sex: <1 Female |
2016 |
51 |
| TX_CURR |
Age/Sex: <1 Female |
2016 |
143 |
| TX_CURR |
Age/Sex: <1 Male |
2016 |
51 |
| TX_CURR |
Age/Sex: <1 Male |
2016 |
145 |
| TX_CURR |
Age/Sex: 1-4 Female |
2016 |
126 |
| TX_CURR |
Age/Sex: 1-4 Female |
2016 |
325 |
| TX_CURR |
Age/Sex: 1-4 Male |
2016 |
126 |
| TX_CURR |
Age/Sex: 1-4 Male |
2016 |
327 |
| TX_CURR |
Age/Sex: 5-14 Female |
2016 |
502 |
| TX_CURR |
Age/Sex: 5-14 Female |
2016 |
1,403 |
| TX_CURR |
Age/Sex: 5-14 Male |
2016 |
502 |
| TX_CURR |
Age/Sex: 5-14 Male |
2016 |
1,280 |
| TX_CURR |
Aggregated Age/Sex: <1 Female |
2016 |
7 |
| TX_CURR |
Aggregated Age/Sex: <1 Male |
2016 |
7 |
| TX_CURR |
Aggregated Age/Sex: 15+ Female |
2016 |
401 |
| TX_CURR |
Aggregated Age/Sex: 15+ Male |
2016 |
268 |
| TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2016 |
23,620 |
| TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2016 |
24,301 |
| TX_CURR |
Sum of age/sex disaggregates |
2016 |
24,301 |
| TX_CURR |
Sum of Age/Sex disaggregations |
2016 |
23,618 |
| TX_CURR |
Sum of Aggregated Age/Sex (<1 and 1-14) <15 |
2016 |
37 |
| TX_CURR |
Sum of Aggregated Age/Sex (<1 and 1-14) <15 |
2016 |
37 |
| TX_CURR |
Sum of Aggregated Age/Sex 15+ |
2016 |
669 |
| TX_CURR |
Sum of Aggregated Age/Sex disaggregates |
2016 |
669 |
| TX_NEW |
By Age/Sex: <1 Female |
2016 |
15 |
| TX_NEW |
By Age/Sex: <1 Male |
2016 |
14 |
| TX_NEW |
By Age/Sex: 1-4 Female |
2016 |
26 |
| TX_NEW |
By Age/Sex: 1-4 Male |
2016 |
25 |
| TX_NEW |
By Age/Sex: 10-14 Female |
2016 |
104 |
| TX_NEW |
By Age/Sex: 10-14 Male |
2016 |
91 |
| TX_NEW |
By Age/Sex: 15-19 Female |
2016 |
307 |
| TX_NEW |
By Age/Sex: 15-19 Male |
2016 |
223 |
| TX_NEW |
By Age/Sex: 20-24 Female |
2016 |
703 |
| TX_NEW |
By Age/Sex: 20-24 Male |
2016 |
396 |
| TX_NEW |
By Age/Sex: 25-49 Female |
2016 |
1,496 |
| TX_NEW |
By Age/Sex: 25-49 Male |
2016 |
886 |
| TX_NEW |
By Age/Sex: 5-9 Female |
2016 |
42 |
| TX_NEW |
By Age/Sex: 5-9 Male |
2016 |
40 |
| TX_NEW |
By Age/Sex: 50+ Female |
2016 |
399 |
| TX_NEW |
By Age/Sex: 50+ Male |
2016 |
396 |
| TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2016 |
5,163 |
| TX_NEW |
Pregnancy status |
2016 |
327 |
| TX_NEW |
Sum of Age/Sex disaggregates |
2016 |
5,163 |
| TX_RET |
Number of adults and children who are still alive and on treatment at 12 months after initiating ART |
2016 |
4,018 |
| TX_RET |
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up |
2016 |
6,197 |
| VMMC_AE |
Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) |
2016 |
79 |
| VMMC_CIRC |
By Age: <1 |
2016 |
2 |
| VMMC_CIRC |
By Age: 1-9 |
2016 |
8 |
| VMMC_CIRC |
By Age: 10-14 |
2016 |
1,280 |
| VMMC_CIRC |
By Age: 15-19 |
2016 |
1,565 |
| VMMC_CIRC |
By Age: 20-24 |
2016 |
1,852 |
| VMMC_CIRC |
By Age: 50+ |
2016 |
272 |
| VMMC_CIRC |
By circumcision technique: Surgical VMMC |
2016 |
7,900 |
| VMMC_CIRC |
By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery |
2016 |
7,900 |
| VMMC_CIRC |
By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) |
2016 |
7,559 |
| VMMC_CIRC |
By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) |
2016 |
341 |
| VMMC_CIRC |
Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period |
2016 |
7,900 |
| VMMC_CIRC |
Sum of age disaggregates |
2016 |
4,979 |
